A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative agent of coronavirus disease 2019 (COVID-19), may lead to severe systemic inflammatory response, pulmonary damage, and even acute respiratory distress syndrome (ARDS). This in turn may result in respira...

Descripción completa

Detalles Bibliográficos
Autores principales: Fragoso-Saavedra, Sergio, Iruegas-Nunez, David A., Quintero-Villegas, Alejandro, García-González, H. Benjamín, Nuñez, Isaac, Carbajal-Morelos, Sergio L., Audelo-Cruz, Belem M., Arias-Martínez, Sarahi, Caro-Vega, Yanink, Calva, Juan José, Luqueño-Martínez, Verónica, González-Duarte, Alejandra, Crabtree-Ramírez, Brenda, Crispín, José C., Sierra-Madero, Juan, Belaunzarán-Zamudio, Pablo F., Valdés-Ferrer, Sergio I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563903/
https://www.ncbi.nlm.nih.gov/pubmed/33066761
http://dx.doi.org/10.1186/s12879-020-05485-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563903/
https://www.ncbi.nlm.nih.gov/pubmed/33066761
http://dx.doi.org/10.1186/s12879-020-05485-7

Ejemplares similares